Zacks restated their neutral rating on shares of Pure Bioscience (NASDAQ: PURE) in a report released on Monday, AnalystRatings.

(RTTNews.com) - PURE Bioscience, Inc. (PURE.OB) reported that its third-quarter net loss was $1.5 million or $0.14 per share, an improvement from a net loss of $1.8 million or $0.31 per share in the same quarter last year.

PURE Bioscience, Inc. (OTCQB: PURE) , the creator of the patented silver dihydrogen citrate (SDC) antimicrobial, shipped an opening order of PURE Hard Surface and PURE Multi-Purpose Cleaner Concentrate to European distributor and Italian export ...

SAN DIEGO, CA, Jun 07, 2013 (Marketwired via COMTEX) -- PURE Bioscience, Inc. (otcqb:PURE), the creator of the patented silver dihydrogen citrate (SDC) antimicrobial, shipped an opening order of PURE Hard Surface and PURE Multi-Purpose Cleaner ...

Jun 17, 2013 (Menafn - M2 EQUITYBITES via COMTEX) --Antimicrobial company PURE Bioscience Inc (otcqb:PURE) announced on Friday its net loss of USD1.5m (USD0.14 per share) for its fiscal third quarter ended 30 April 2013.

SAN DIEGO, CA, Jun 14, 2013 (Menafn - Marketwired via COMTEX) --PURE Bioscience, Inc. (otcqb:PURE), creator of the patented silverdihydrogen citrate (SDC) antimicrobial, reported results for itsfiscal third quarter ended April 30, 2013.

Pure Bioscience logo Pure Bioscience (NASDAQ: PURE)'s stock had its �neutral� rating restated by Zacks in a report released on Monday, Analyst Ratings Network reports.

Pure Bioscience, Inc. engages in the discovery, development, and commercialization of bioscience products principally in the United States.

PURE Bioscience (OTCMKTS:PURE) closed at $0.410 on a traded volume of 14,102 shares, in comparison to 83,500 shares of average trading volume.

PURE Bioscience (OTCMKTS: PURE) plunged -4.26% and closed at $0.450 on a traded volume of 43,864 shares, whereas its average trading volume is 103,168 shares.